A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and older - Zhang, Yuhui; Wang, Yanxia; Li, Guangfu; Zhao, Xue; Wang, Kai; Jia, Chunyu; Yang, Yongli; Huang, Lili; Tan, Jiebing; Chen, Xiaofen; Leng, Wenna; Xie, Zhiqiang; et al. (Vaccine, 2024)
Keywords: 23-valent pneumococcal polysaccharide vaccine; Adverse events; Age; Allergy and Immunology; antibodies; Antibodies, Bacterial; Biochemistry; Biotechnology; Blood; blood serum; China; Clinical trial; Clinical trials; Disease control; Disease prevention; Enzyme-linked immunosorbent assay; enzymes; Erythema; Guillain-Barre syndrome; Health care; Humans; IgG antibody; Immunization; Immunogenicity; Immunogenicity, Vaccine; Immunoglobulin G; Injection; injection site; intramuscular injection; Mortality; Older people; pain; people; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines; Pneumonia; Polysaccharides; Public health; Safety; Seroconversion; Serotypes; Side effects; Streptococcus infections; Streptococcus pneumoniae; Vaccination; Vaccines; Vaccines, Conjugate; China; Henan China; Clinical trial; Safety; Immunogenicity; Streptococcus pneumoniae; 23-valent pneumococcal polysaccharide vaccine